SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am. 2003; 30: 209-217.
  • 2
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 2095-2101.
  • 3
    van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009; 55: 1-8.
  • 4
    Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008; 100: 1144-1154.
  • 5
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
  • 6
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 7
    Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004; 5: 101-106.
  • 8
    Schroder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2003; 92( suppl 2): 1-13.
  • 9
    Hugosson J, Aus G, Bergdahl S, et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int. 2003; 92 ( suppl 2): 39-43.
  • 10
    Schröder FH, Roobol MJ. The European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results. BJU Int. 2003; 92( suppl 2): 1117.
  • 11
    van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007; 52: 1560-1563.
  • 12
    Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002; 167: 1664-1669.
  • 13
    Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003; 61: 365-369.
  • 14
    van den Bergh RC, Essink-Bot ML, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009; 115: 3868-3878.
  • 15
    Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009; 27: 398-403.
  • 16
    Fall K, Garmo H, Andrén O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007; 99: 526-532.
  • 17
    van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schroder FH, Bangma CH. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer—a review. Eur Urol. 2008; 54: 505-516.
  • 18
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868-878.
  • 19
    Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006; 175: 1298-1302; discussion 1302-1303.
  • 20
    Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006; 98: 355-357.
  • 21
    Khatami A, Damber JE, Lodding P, Pihl CG, Hugosson J. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?—A case control study. Scand J Urol Nephrol. 2003; 37: 213-217.
  • 22
    Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004; 171: 1520-1524.
  • 23
    Nam RK, Jewett MA, Krahn MD, et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol. 2003; 10: 1891-1898.
  • 24
    Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol. 2004; 172( 5 pt 1): 1835-1839.